A BioRxiv Medical Journal Article Has Been Published Today On Nucana "A Phosphoramidate Modification Of FUDR, NUC-3373, Causes DNA Damage And DAMPs Release From Colorectal Cancer Cells, Potentiating Lymphocyte-Induced Cell Death"
Portfolio Pulse from Benzinga Newsdesk
A BioRxiv article discusses the potential of NUC-3373, a phosphoramidate modification of FUDR, to enhance immunogenicity in colorectal cancer cells, potentially improving the efficacy of immunotherapies. The study shows that NUC-3373 can cause DNA damage and release DAMPs, increasing lymphocyte-induced cell death.
October 11, 2024 | 4:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nucana's NUC-3373 shows potential in enhancing immunogenicity in colorectal cancer cells, which could improve the effectiveness of immunotherapies. This development may attract investor interest and impact Nucana's stock positively.
The study highlights NUC-3373's ability to enhance immunogenicity in colorectal cancer cells, which is significant for Nucana as it could lead to improved treatment options and increased interest in their product. This positive development is likely to have a favorable impact on Nucana's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90